{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:05:06Z","timestamp":1793840706924,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.vaccine.2005.08.027","type":"journal-article","created":{"date-parts":[[2005,8,25]],"date-time":"2005-08-25T07:29:37Z","timestamp":1124954977000},"page":"4582-4585","source":"Crossref","is-referenced-by-count":245,"title":["Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center"],"prefix":"10.1016","volume":"24","author":[{"given":"P.J.","family":"Bergman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Camps-Palau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.F.","family":"Leibman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Craft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Hohenhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Wolchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2005.08.027_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/07357908609017520","article-title":"Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum","volume":"4","author":"MacEwen","year":"1986","journal-title":"Cancer Invest"},{"issue":"6","key":"10.1016\/j.vaccine.2005.08.027_bib2","first-page":"580","article-title":"Prognostic criteria for dogs with oral melanoma","volume":"178","author":"Harvey","year":"1981","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"10.1016\/j.vaccine.2005.08.027_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1939-1676.1994.tb03231.x","article-title":"0-7-21 radiation therapy for the treatment of canine oral melanoma","volume":"8","author":"Bateman","year":"1994","journal-title":"J Vet Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.027_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/030098587901600103","article-title":"Prognosis after surgical excision of canine melanomas","volume":"16","author":"Bostock","year":"1979","journal-title":"Vet Pathol"},{"issue":"6","key":"10.1016\/j.vaccine.2005.08.027_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1354\/vp.37-6-597","article-title":"Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases","volume":"37","author":"Ramos-Vara","year":"2000","journal-title":"Vet Pathol"},{"issue":"11","key":"10.1016\/j.vaccine.2005.08.027_bib6","first-page":"1553","article-title":"Immunotherapeutic approaches for the treatment of malignant melanoma","volume":"2","author":"Curiel-Lewandrowski","year":"2001","journal-title":"Curr Opin Invest Drugs"},{"issue":"10","key":"10.1016\/j.vaccine.2005.08.027_bib7","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/1097-0142(19931115)72:10<3091::AID-CNCR2820721034>3.0.CO;2-V","article-title":"Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis","volume":"72","author":"Sirott","year":"1993","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.027_bib8","first-page":"96","article-title":"Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987\u20131997)","volume":"17","author":"Freeman","year":"2003","journal-title":"J Vet Intern Med"},{"issue":"6","key":"10.1016\/j.vaccine.2005.08.027_bib9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0039-6109(05)70519-3","article-title":"Medical treatment of metastatic melanoma","volume":"76","author":"Houghton","year":"1996","journal-title":"Surg Clin North Am"},{"issue":"4","key":"10.1016\/j.vaccine.2005.08.027_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1470-2045(00)00290-4","article-title":"Vaccines for melanoma: translating basic immunology into new therapies","volume":"2","author":"Wolchok","year":"2001","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.vaccine.2005.08.027_bib11","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.vaccine.2005.08.027_bib12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.2460\/javma.2001.218.1444","article-title":"Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases","volume":"218","author":"Rassnick","year":"2001","journal-title":"J Am Vet Med Assoc"},{"issue":"3","key":"10.1016\/j.vaccine.2005.08.027_bib13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1740-8261.2003.tb00468.x","article-title":"A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation","volume":"44","author":"Proulx","year":"2003","journal-title":"Vet Radiol Ultrasound"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.027_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.cgt.7700015","article-title":"Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs","volume":"6","author":"Hogge","year":"1999","journal-title":"Cancer Gene Ther"},{"issue":"13","key":"10.1016\/j.vaccine.2005.08.027_bib15","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1089\/hum.1998.9.13-1851","article-title":"Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer","volume":"9","author":"Hogge","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2005.08.027_bib16","first-page":"4249","article-title":"Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor","volume":"5","author":"MacEwen","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.vaccine.2005.08.027_bib17","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI510","article-title":"In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma","volume":"101","author":"Dow","year":"1998","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.vaccine.2005.08.027_bib18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1089\/10430340050032447","article-title":"A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma University of Colorado Cancer Center Clinical Trial","volume":"11","author":"Walsh","year":"2000","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2005.08.027_bib19","first-page":"1104","article-title":"Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2","volume":"3","author":"Quintin-Colonna","year":"1996","journal-title":"Gene Ther"},{"issue":"9","key":"10.1016\/j.vaccine.2005.08.027_bib20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.cgt.7700625","article-title":"Enhancing antimelanoma immune responses through apoptosis","volume":"10","author":"Bianco","year":"2003","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.027_bib21","first-page":"56","article-title":"Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen","volume":"19","author":"Gyorffy","year":"2005","journal-title":"J Vet Intern Med"},{"issue":"5388","key":"10.1016\/j.vaccine.2005.08.027_bib22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.282.5388.476","article-title":"Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine","volume":"282","author":"Wang","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.027_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1385\/IR:25:1:53","article-title":"Vaccine development against HIV-1: current perspectives and future directions","volume":"25","author":"Edgeworth","year":"2002","journal-title":"Immunol Res"},{"issue":"6","key":"10.1016\/j.vaccine.2005.08.027_bib24","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1172\/JCI4004","article-title":"Tumor immunity and autoimmunity induced by immunization with homologous DNA","volume":"102","author":"Weber","year":"1998","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2005.08.027_bib25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0889-8588(05)70026-5","article-title":"Vaccines and other adjuvant therapies for melanoma","volume":"12","author":"Wolchok","year":"1998","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1016\/j.vaccine.2005.08.027_bib26","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1084\/jem.169.6.2029","article-title":"Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA","volume":"169","author":"Bouchard","year":"1989","journal-title":"J Exp Med"},{"issue":"12 Part 1","key":"10.1016\/j.vaccine.2005.08.027_bib27","first-page":"2191","article-title":"Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization","volume":"3","author":"Ross","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.027_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/scbi.2001.0397","article-title":"Strategies to overcome immune ignorance and tolerance","volume":"12","author":"Perales","year":"2002","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.vaccine.2005.08.027_bib29","first-page":"1284","article-title":"Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial","volume":"9","author":"Bergman","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05008248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05008248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T06:29:27Z","timestamp":1552890567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X05008248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":29,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0264410X05008248"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2005.08.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}